SEARCH RESULT

Total Matching Records found : 2393

Editor-in-Chief of Bihar-Dhirendra K Jha

How an image-fixated chief minister has bent the state’s media to his will If you haven’t heard of an income tax raid on the residential premises of Nitish Kumar’s close aide and treasurer of the ruling Janata Dal-United (JD-U), Vinay Kumar Sinha, you are not alone. Thanks to the local media, it took a while even in Patna—where the house is located—for people to get to know. This, incidentally, is the...

More »

The Ghost’s In The Details, Ma’am-Aakar Patel

Arundhati has got it all wrong—the facts speak out against her romantic notions of the tribals’ fight Nirad C. Chaudhary wrote in The Continent of Circe that India’s tribals were mainly found in hill forests. This was because, he reasoned, they had been chased there by the invading Aryans, who displaced them from their river plains. In an essay published in this magazine (Capitalism: A Ghost Story, March 26), Arundhati Roy...

More »

Western warnings-R Ramachandran

India is coming under increasing pressure from the U.S. and the European Union for the strict patentability criteria it applies for medicines. AS was only to be expected, the two landmark decisions made by the Indian patent office in recent times concerning pharmaceutical patent cases have not gone down well with the multinational drug industry. First, there was the rejection in 2006 of the patent application by the Swiss multinational...

More »

Patent to plunder -Amit Sengupta

India's efforts to produce and supply life-saving drugs at affordable prices face challenges from multinational companies trying to “evergreen” their patents. THE average life expectancy across the globe has increased from around 30 years a century ago to over 65 years today. This has been made possible in large part by modern medicine. Never before in history have humans had access to such an array of medicines and devices to...

More »

A welcome first -TK Rajalakshmi

Industry reacts with caution to the grant of a compulsory licence to Natco, but cancer patients welcome it and hope for many more. THE first compulsory licence (CL) issued by the Indian patent office, to the local drug manufacturer Natco Pharma Ltd to sell the generic version of Bayer AG's anti-cancer drug Nexavar, has led to varied reactions. The landmark decision has also raised concerns about the outcome of cases...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close